BCL-2 mutant B7H6-CAR-T cells synergized with venetoclax for treating small cell lung cancer

Area of Science:

• Oncology
• Immunotherapy
• Cancer Biology

Background:

• Small cell lung cancer (SCLC) presents a poor prognosis due to rapid proliferation and early metastasis.
• Current chimeric antigen receptor (CAR) T-cell therapies face limitations in solid tumors, including SCLC, due to target antigen scarcity and suboptimal efficacy.
• There is a critical need for innovative therapeutic strategies to improve outcomes for SCLC patients.

Purpose of the Study:

• To identify novel therapeutic targets for SCLC.
• To develop and evaluate a CAR-T cell-based combination therapy for SCLC.
• To assess the efficacy of B7H6-specific CAR-T cells in combination with venetoclax in preclinical SCLC models.

Main Methods:

• In vitro assessment of B7H6-specific CAR-T cell antitumor activity.
• Engineering of venetoclax-resistant B7H6 CAR-T cells.
• In vitro and in vivo evaluation of the synergistic effects of venetoclax and B7H6 CAR-T cells.

Main Results:

• B7H6 was identified as a highly expressed target antigen in SCLC tumors.
• B7H6-specific CAR-T cells demonstrated antigen-specific antitumor efficacy.
• The combination of venetoclax and BCL-2(D103E)-expressing B7H6-targeting CAR-T cells exhibited significant anti-SCLC activity in vitro and in vivo.

Conclusions:

• The combination of BCL-2 mutant-expressing B7H6-targeting CAR-T cells and venetoclax represents a promising therapeutic strategy for B7H6-expressing SCLCs and potentially other solid tumors.
• This approach provides a foundation for future clinical trials investigating CAR-T cells and proapoptotic small molecules for SCLC treatment.